Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya

Trop Med Int Health. 2008 Jan;13(1):99-107. doi: 10.1111/j.1365-3156.2007.01980.x.

Abstract

Objective: To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya.

Methods: Cross-sectional survey at all government facilities in four Kenyan districts. Main outcome measures were health facility and health worker readiness to implement AL policy; quality of antimalarial prescribing, counselling and drug dispensing in comparison with national guidelines; and factors influencing AL prescribing for treatment of uncomplicated malaria in under-fives.

Results: We evaluated 193 facilities, 227 health workers and 1533 sick-child consultations. Health facility and health worker readiness was variable: 89% of facilities stocked AL, 55% of health workers had access to guidelines, 46% received in-service training on AL and only 1% of facilities had AL wall charts. Of 940 children who needed AL treatment, AL was prescribed for 26%, amodiaquine for 39%, SP for 4%, various other antimalarials for 8% and 23% of children left the facility without any antimalarial prescribed. When AL was prescribed, 92% of children were prescribed correct weight-specific dose. AL dispensing and counselling tasks were variably performed. Higher health worker's cadre, in-service training including AL use, positive malaria test, main complaint of fever and high temperature were associated with better prescribing.

Conclusions: Changes in clinical practices at the point of care might take longer than anticipated. Delivery of successful interventions and their scaling up to increase coverage are important during this process; however, this should be accompanied by rigorous research evaluations, corrective actions on existing interventions and testing cost-effectiveness of novel interventions capable of improving and maintaining health worker performance and health systems to deliver artemisinin-based combination therapy in Africa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ambulatory Care*
  • Antimalarials / administration & dosage
  • Antimalarials / therapeutic use
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins / administration & dosage
  • Artemisinins / therapeutic use*
  • Child, Preschool
  • Cross-Sectional Studies
  • Drug Combinations
  • Ethanolamines
  • Fluorenes / administration & dosage
  • Fluorenes / therapeutic use*
  • Guideline Adherence
  • Health Personnel
  • Health Policy*
  • Humans
  • Infant
  • Infant, Newborn
  • Interviews as Topic
  • Kenya
  • Malaria / drug therapy*
  • Practice Patterns, Physicians'
  • Program Evaluation
  • Sesquiterpenes / administration & dosage
  • Sesquiterpenes / therapeutic use*

Substances

  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Drug Combinations
  • Ethanolamines
  • Fluorenes
  • Sesquiterpenes